Compare AbCellera Biologics Inc (ABCL) vs PubMatic Inc (PUBM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs PubMatic Inc — how do they compare? AbCellera Biologics Inc trades at $7.18 (market cap $2.35B), while PubMatic Inc trades at $12.96 (market cap $619.32M). The key difference: AbCellera Biologics Inc is far larger — about 3.8× PubMatic Inc's market cap. Which is the better fit depends on your goals.
| ABCL | PUBM | |
|---|---|---|
Market Cap | $2.35B | $619.32M |
Sector | Health | Technology |
52-Week High | $8.12 | $13.83 |
52-Week Low | $2.78 | $6.28 |
Enterprise Value | $1.99B | $516.83M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
PubMatic trades at $13.32, down 1.7% over 24 hours, with a bullish technical signal from moving averages and a consensus price target of $17. The company reported a net loss of $14.46M in 2025 despite revenue of $282.93M, though it has beaten earnings expectations in recent quarters. Recent news highlights partnerships and product launches, such as the Creator Marketplace and AgenticOS integrations, aimed at driving growth in digital advertising.
The outlook is mixed: analyst sentiment is evenly split between Buy and Hold, with potential upside to the price target, but profitability concerns and a high P/E ratio of 132 pose risks. Investors should weigh the company's innovation in AI-driven ad tech against ongoing losses and competitive pressures in the programmatic advertising space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
